Maze Reports Q1 Revenue of $20M, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Reports Q1 revenue $20M, consensus $8.5M. License revenue was $20M for Q1. No license revenue was recognized for the quarter ended March 31, 2025. License revenue recognized in Q1 of 2026 reflects the achievement of a milestone pursuant to the exclusive license agreement with Shionogi & Co. for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup. Cash, cash equivalents and marketable securities were $362.9M as of March 31, compared to $360.0M as of December 31, 2025. Maze expects that its cash, cash equivalents and marketable securities as of March 31, together with the proceeds from the registered offering completed in April and a $20M milestone payment received from Shionogi & Co. in April, will fund operations into 2029 based on its current business plan.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAZE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAZE
Wall Street analysts forecast MAZE stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.400
Low
46.00
Averages
52.00
High
60.00
Current: 25.400
Low
46.00
Averages
52.00
High
60.00
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Maze Therapeutics CEO Jason Coloma Sells $847,000 in Shares Amid Stock Fluctuations
- Executive Share Sale: Maze Therapeutics CEO Jason Coloma sold 32,564 shares in May 2026 for approximately $847,000 at an average price of $26.01 per share, with all shares being indirect holdings, indicating confidence in the company's future prospects.
- Stock Price Context: The sale occurred after a 135.3% increase in share price over the past year, and despite a decline from the 52-week high of $53.65 reached in March, Coloma's sale did not raise investor concerns as it was part of a prearranged trading plan.
- Strong Financial Position: Maze Therapeutics ended Q1 2026 with $362.9 million in cash and cash equivalents, providing a financial runway expected to last until 2029, which supports ongoing clinical trial advancements and efforts to secure FDA approval.
- Clinical Trial Progress: The company is advancing precision medicines for complex renal and metabolic disorders, with Phase 2 trials expected later in 2026, showcasing its ongoing innovation capabilities and market potential in the biopharmaceutical sector.
See More
Maze Therapeutics CEO Sells 32,564 Shares
- Significant Transaction Size: Maze Therapeutics CEO Jason Coloma sold 32,564 common shares between May 22 and May 26, 2026, for approximately $847,000, marking his largest single sale to date, exceeding the average historical sale size of about 17,251 shares, which reflects confidence in the company's prospects.
- Market Performance Correlation: This sale coincided with a remarkable 164.34% total return for Maze Therapeutics shares over the past year, with the transaction occurring at a price of around $26.01, compared to a market close of $26.35 on the final sale date, indicating volatility driven by encouraging clinical trial data.
- Ownership Structure Impact: Following the transaction, Coloma retains 379,510 shares indirectly held through family trusts, indicating substantial remaining equity and a lack of urgency to liquidate holdings, which suggests confidence in the company's future.
- Compliance with Trading Plan: The sale was executed under a prearranged Rule 10b5-1 trading plan established in February 2026, designed to avoid accusations of insider trading, demonstrating that the transaction is part of routine portfolio management rather than a negative signal regarding the company's outlook.
See More
Maze Therapeutics CEO Sells Over 30,000 Shares: Implications for Investors
- Significant Transaction Size: Jason Coloma, CEO of Maze Therapeutics, sold 32,564 common shares between May 22 and May 26, 2026, for approximately $847,000, marking the largest single sale in his history, exceeding the average historical sale size of about 17,251 shares, indicating his responsiveness to market dynamics.
- Market Performance Correlation: This sale coincided with a remarkable 164.34% total return for Maze Therapeutics shares over the past year, with the transaction occurring at a price of around $26.01, compared to a market close of $26.35 on the final sale date, highlighting the connection between Coloma's sale and stock price fluctuations.
- Ownership Structure Post-Transaction: Following the sale, Coloma retains 379,510 shares indirectly held through family trusts, indicating substantial remaining equity and a lack of urgency to liquidate his holdings, reflecting confidence in the company's future prospects.
- Compliance with Trading Plan: Coloma's sale was executed under a prearranged Rule 10b5-1 trading plan established in February 2026, designed to mitigate legal risks associated with insider trading, suggesting that the sale is part of routine portfolio management rather than a negative outlook on the company’s future.
See More
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge
- Share Reduction Details: HighVista Strategies disclosed the sale of 70,503 shares of Maze Therapeutics in Q1 2026, an estimated trade valued at $3.11 million, indicating a strategic adjustment in its holdings.
- Ownership Proportion Change: Following this sale, HighVista's stake in Maze Therapeutics decreased to 99,850 shares worth $2.98 million, representing only 0.82% of its reported assets under management, reflecting a cautious stance towards the stock.
- Stock Performance: As of May 14, 2026, Maze Therapeutics shares were priced at $26.43, marking a 180% increase over the past year, significantly outperforming the S&P 500's 25% gain, indicating strong market recognition of its potential.
- Clinical Progress and Market Reaction: Despite reporting positive data for MZE829 in clinical trials, Maze's stock plummeted over 30% post-announcement due to investor concerns about competing therapies, highlighting the market's sensitivity to biotech stock fluctuations.
See More
Maze Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Maze Therapeutics reported a Q1 GAAP EPS of -$0.45, beating expectations by $0.10, indicating an improvement in financial performance despite ongoing losses.
- License Revenue Surge: The company achieved $20 million in license revenue for Q1, exceeding market expectations by $11.5 million, suggesting increasing market acceptance and demand for its products.
- Stable Cash Reserves: As of March 31, 2026, Maze's cash, cash equivalents, and marketable securities totaled $362.9 million, a slight increase from $360.0 million on December 31, 2025, demonstrating solid financial management.
- Future Funding Outlook: Maze anticipates that its cash reserves, along with proceeds from the registered offering completed in April 2026 and a $20 million milestone payment from Shionogi & Co., Ltd., will fund operations into 2029, reflecting confidence in its future growth plans.
See More
Maze Therapeutics Executive Stock Transaction Overview
- Executive Stock Transaction: Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and immediately sold 7,500 shares of common stock on April 29, 2026, for approximately $190,000, indicating a strategic liquidity management approach by the company's executives.
- Holding Changes: Dandekar's direct stock holdings were reduced by 41.66%, yet he retains 44,143 stock options, suggesting ongoing potential for equity exposure and continued interest in the company's future prospects.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan, reflecting consistency with prior administrative transactions, and while the trade size has decreased, it still demonstrates Dandekar's confidence in the company's trajectory.
- Market Performance: Maze Therapeutics' stock has surged by 192% over the past year, closing at $25.68 on April 29, 2026, highlighting the company's strong growth potential in the biopharmaceutical sector.
See More
Maze Therapeutics CEO Jason Coloma Sells $847,000 in Shares Amid Stock Fluctuations
- Executive Share Sale: Maze Therapeutics CEO Jason Coloma sold 32,564 shares in May 2026 for approximately $847,000 at an average price of $26.01 per share, with all shares being indirect holdings, indicating confidence in the company's future prospects.
- Stock Price Context: The sale occurred after a 135.3% increase in share price over the past year, and despite a decline from the 52-week high of $53.65 reached in March, Coloma's sale did not raise investor concerns as it was part of a prearranged trading plan.
- Strong Financial Position: Maze Therapeutics ended Q1 2026 with $362.9 million in cash and cash equivalents, providing a financial runway expected to last until 2029, which supports ongoing clinical trial advancements and efforts to secure FDA approval.
- Clinical Trial Progress: The company is advancing precision medicines for complex renal and metabolic disorders, with Phase 2 trials expected later in 2026, showcasing its ongoing innovation capabilities and market potential in the biopharmaceutical sector.
See More
Maze Therapeutics CEO Sells 32,564 Shares
- Significant Transaction Size: Maze Therapeutics CEO Jason Coloma sold 32,564 common shares between May 22 and May 26, 2026, for approximately $847,000, marking his largest single sale to date, exceeding the average historical sale size of about 17,251 shares, which reflects confidence in the company's prospects.
- Market Performance Correlation: This sale coincided with a remarkable 164.34% total return for Maze Therapeutics shares over the past year, with the transaction occurring at a price of around $26.01, compared to a market close of $26.35 on the final sale date, indicating volatility driven by encouraging clinical trial data.
- Ownership Structure Impact: Following the transaction, Coloma retains 379,510 shares indirectly held through family trusts, indicating substantial remaining equity and a lack of urgency to liquidate holdings, which suggests confidence in the company's future.
- Compliance with Trading Plan: The sale was executed under a prearranged Rule 10b5-1 trading plan established in February 2026, designed to avoid accusations of insider trading, demonstrating that the transaction is part of routine portfolio management rather than a negative signal regarding the company's outlook.
See More
Maze Therapeutics CEO Sells Over 30,000 Shares: Implications for Investors
- Significant Transaction Size: Jason Coloma, CEO of Maze Therapeutics, sold 32,564 common shares between May 22 and May 26, 2026, for approximately $847,000, marking the largest single sale in his history, exceeding the average historical sale size of about 17,251 shares, indicating his responsiveness to market dynamics.
- Market Performance Correlation: This sale coincided with a remarkable 164.34% total return for Maze Therapeutics shares over the past year, with the transaction occurring at a price of around $26.01, compared to a market close of $26.35 on the final sale date, highlighting the connection between Coloma's sale and stock price fluctuations.
- Ownership Structure Post-Transaction: Following the sale, Coloma retains 379,510 shares indirectly held through family trusts, indicating substantial remaining equity and a lack of urgency to liquidate his holdings, reflecting confidence in the company's future prospects.
- Compliance with Trading Plan: Coloma's sale was executed under a prearranged Rule 10b5-1 trading plan established in February 2026, designed to mitigate legal risks associated with insider trading, suggesting that the sale is part of routine portfolio management rather than a negative outlook on the company’s future.
See More
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge
- Share Reduction Details: HighVista Strategies disclosed the sale of 70,503 shares of Maze Therapeutics in Q1 2026, an estimated trade valued at $3.11 million, indicating a strategic adjustment in its holdings.
- Ownership Proportion Change: Following this sale, HighVista's stake in Maze Therapeutics decreased to 99,850 shares worth $2.98 million, representing only 0.82% of its reported assets under management, reflecting a cautious stance towards the stock.
- Stock Performance: As of May 14, 2026, Maze Therapeutics shares were priced at $26.43, marking a 180% increase over the past year, significantly outperforming the S&P 500's 25% gain, indicating strong market recognition of its potential.
- Clinical Progress and Market Reaction: Despite reporting positive data for MZE829 in clinical trials, Maze's stock plummeted over 30% post-announcement due to investor concerns about competing therapies, highlighting the market's sensitivity to biotech stock fluctuations.
See More
Maze Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Maze Therapeutics reported a Q1 GAAP EPS of -$0.45, beating expectations by $0.10, indicating an improvement in financial performance despite ongoing losses.
- License Revenue Surge: The company achieved $20 million in license revenue for Q1, exceeding market expectations by $11.5 million, suggesting increasing market acceptance and demand for its products.
- Stable Cash Reserves: As of March 31, 2026, Maze's cash, cash equivalents, and marketable securities totaled $362.9 million, a slight increase from $360.0 million on December 31, 2025, demonstrating solid financial management.
- Future Funding Outlook: Maze anticipates that its cash reserves, along with proceeds from the registered offering completed in April 2026 and a $20 million milestone payment from Shionogi & Co., Ltd., will fund operations into 2029, reflecting confidence in its future growth plans.
See More
Maze Therapeutics Executive Stock Transaction Overview
- Executive Stock Transaction: Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and immediately sold 7,500 shares of common stock on April 29, 2026, for approximately $190,000, indicating a strategic liquidity management approach by the company's executives.
- Holding Changes: Dandekar's direct stock holdings were reduced by 41.66%, yet he retains 44,143 stock options, suggesting ongoing potential for equity exposure and continued interest in the company's future prospects.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan, reflecting consistency with prior administrative transactions, and while the trade size has decreased, it still demonstrates Dandekar's confidence in the company's trajectory.
- Market Performance: Maze Therapeutics' stock has surged by 192% over the past year, closing at $25.68 on April 29, 2026, highlighting the company's strong growth potential in the biopharmaceutical sector.
See More
